Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology.
Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, McGhee S, Perez EE, Raasch J, Scherzer R, Schroeder H, Seroogy C, Huissoon A, Sorensen RU, Katial R. Orange JS, et al. Among authors: schroeder h. J Allergy Clin Immunol. 2012 Sep;130(3 Suppl):S1-24. doi: 10.1016/j.jaci.2012.07.002. J Allergy Clin Immunol. 2012. PMID: 22935624
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM. Wasserman RL, et al. Among authors: schroeder h. J Clin Immunol. 2012 Aug;32(4):663-9. doi: 10.1007/s10875-012-9656-5. Epub 2012 Mar 6. J Clin Immunol. 2012. PMID: 22392046 Free PMC article. Clinical Trial.
Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G. Roifman CM, et al. Among authors: schroeder h. Int Immunopharmacol. 2003 Sep;3(9):1325-33. doi: 10.1016/s1567-5769(03)00134-6. Int Immunopharmacol. 2003. PMID: 12890430 Clinical Trial.
Correction to: MET receptor serves as a promising target in melanoma brain metastases.
Redmer T, Schumann E, Peters K, Weidemeier ME, Nowak S, Schroeder HWS, Vidal A, Radbruch H, Lehmann A, Kreuzer-Redmer S, Jürchott K, Radke J. Redmer T, et al. Among authors: schroeder hws. Acta Neuropathol. 2024 Mar 27;147(1):63. doi: 10.1007/s00401-024-02719-9. Acta Neuropathol. 2024. PMID: 38536477 Free PMC article. No abstract available.
MET receptor serves as a promising target in melanoma brain metastases.
Redmer T, Schumann E, Peters K, Weidemeier ME, Nowak S, Schroeder HWS, Vidal A, Radbruch H, Lehmann A, Kreuzer-Redmer S, Jürchott K, Radke J. Redmer T, et al. Among authors: schroeder hws. Acta Neuropathol. 2024 Feb 22;147(1):44. doi: 10.1007/s00401-024-02694-1. Acta Neuropathol. 2024. PMID: 38386085 Free PMC article.
1,404 results